We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Ban of CFC in Inhalers Spurs Product Innovation

By HospiMedica International staff writers
Posted on 06 Oct 2008
The respiratory disposables and reusable respiratory accessories market is undergoing a dramatic change caused in part by a recent U.S. More...
government regulation that bans the use of chlorofluorocarbon (CFC) in inhalers.

A new report by Kalorama Information (New York, NY, USA) has found that more than 95% of inhalers used today contain ozone-depleting CFC as a propellant. To abide by international environmental guidelines, the United States released a new policy in 2005 that decreed that CFCs must be removed from inhalers by December 31, 2008, and be replaced with hydrofluoroalkane (HFA). As a result, inhaler equipment suppliers and pharmaceutical companies have been collaborating to face the phase-out, and are undertaking compound stability and product compatibility tests as a requirement for approval by the U.S. Food and Drug Administration (FDA). These new non-CFC inhalers will not see generic competition until they come off patent starting in 2010, and are therefore predicted to cost about twice as much as CFC inhalers. As a result, inhalers, which make up the lion's share of the U.S. US$36 billion market for respiratory devices, are expected to enjoy a strong 9.8% annual growth rate through 2012, spurred in part by new product innovations following the CFC ban.

"Compliance could be a blessing in disguise for inhaler companies,” said research analyst Joe Constance of Kalorama Information. "Until December 2007, companies with CFC-based products were allowed to market their product, so they have had sufficient time to take the necessary steps to shift towards HFA based products. And the companies did not need to make any significant changes in their manufacturing processes in order to abide by this new government regulation.”

HFA inhalers are designed to give the same dose of albuterol as current CFC inhalers. However, since HFAs are a different type of propellant, the albuterol HFA inhalers may taste and feel different. The force of the spray may feel softer from albuterol HFA than from albuterol CFC inhalers, and often hits the back of the mouth as a fine mist. Importantly, albuterol HFA inhalers have to be cleaned, dried, and primed to supply the right dose of medicine.

Related Links:
Kalorama Information


Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Xenon Light Source
CLV-S400
Infant Incubator
OKM 801
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.